Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer

被引:10
作者
Osako, Tomo [1 ,3 ]
Ito, Yoshinori [1 ]
Ushijima, Masaru [2 ]
Takahashi, Shunji [1 ]
Tokudome, Nahomi [1 ]
Sugihara, Tsutomu [1 ]
Iwase, Takuji [3 ]
Matsuura, Masaaki [2 ,4 ]
Hatake, Kiyohiko [1 ]
机构
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Koto Ku, Tokyo 1358550, Japan
[2] Japanese Fdn Canc Res, Bioinformat Grp, Genome Ctr, Tokyo 1358550, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Breast Oncol, Tokyo 1358550, Japan
[4] Japanese Fdn Canc Res, Inst Canc, Dept Canc Genom, Tokyo 1358550, Japan
关键词
Capecitabine; Metastatic breast cancer; Predictive factors; Time to treatment failure; Overall survival; ADVANCED COLORECTAL-CANCER; STEROID-HORMONE RECEPTORS; PROGNOSTIC FACTORS; PHASE-II; ESTROGEN-RECEPTORS; ORAL CAPECITABINE; LIVER METASTASES; CHEMOTHERAPY; TRIAL; TRASTUZUMAB;
D O I
10.1007/s00280-008-0806-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC). A total of 102 consecutive patients with MBC who had been administered capecitabine monotherapy between June 2003 and August 2004 were retrospectively reviewed. Capecitabine (828 mg/m(2)) was given twice daily for 3 weeks followed by a 1-week rest period; this was repeated every 4 weeks. We evaluated the potential clinical factors for TTF and OS, using univariate analysis (log-rank test) and the multivariate Cox regression model. Median follow-up was 16.9 months. A total of 100 patients (98%) had been pretreated with either anthracyclines or taxanes, and 81 patients (79%) with both anthracyclines and taxanes. Response rate was 17% and clinical benefit rate was 41%. Median TTF and OS were 4.9 and 24.3 months, respectively. Multivariate analysis demonstrated that no liver metastasis (P = 0.015), good performance status (P = 0.033), longer disease-free interval (P = 0.036), and hormone receptor-positive tumor (P = 0.038) were significant for TTF. No liver metastasis (P = 0.00012), objective response to capecitabine (P = 0.00084), and good performance status (P = 0.0011) were significant for OS. Capecitabine monotherapy is effective over the long term for heavily pretreated patients with MBC who have no liver metastasis, good performance status, longer disease-free interval, or hormone receptor-positive tumor. Patients who have no liver metastasis, who respond to capecitabine, or who have good performance status are expected to survive even longer.
引用
收藏
页码:865 / 871
页数:7
相关论文
共 34 条
[1]   COMBINATION CHEMOTHERAPY FOR METASTATIC OR RECURRENT CARCINOMA OF THE BREAST - A RANDOMIZED PHASE-III TRIAL COMPARING CAF VERSUS VATH VERSUS VATH ALTERNATING WITH CMFVP - CANCER AND LEUKEMIA GROUP-B STUDY-8281 [J].
AISNER, J ;
CIRRINCIONE, C ;
PERLOFF, M ;
PERRY, M ;
BUDMAN, D ;
ABRAMS, J ;
PANASCI, L ;
MUSS, H ;
CITRON, M ;
HOLLAND, J ;
WOOD, W ;
HENDERSON, IC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1443-1452
[2]  
ALLEGRA JC, 1978, CANCER RES, V38, P4299
[3]   The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Brown, A ;
Smith, R ;
Mamounas, EP ;
Fisher, B ;
Margolese, R ;
Theoret, H ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174
[4]   BREAST CANCERS - ESTROGEN AND PROGESTERONE-RECEPTOR STATUS AS A PREDICTOR OF INVITRO CHEMOTHERAPEUTIC RESPONSE [J].
BERTELSEN, CA ;
GIULIANO, AE ;
KERN, DH ;
MANN, BD ;
ROE, DJ ;
MORTON, DL .
JOURNAL OF SURGICAL RESEARCH, 1984, 37 (04) :257-263
[5]   PROGNOSTIC FACTORS IN RECURRENT BREAST-CANCER - RELATIONSHIPS TO SITE OF RECURRENCE, DISEASE-FREE INTERVAL, FEMALE SEX STEROID-RECEPTORS, PLOIDY AND HISTOLOGICAL MALIGNANCY GRADING [J].
BLANCO, G ;
HOLLI, K ;
HEIKKINEN, M ;
KALLIONIEMI, OP ;
TASKINEN, P .
BRITISH JOURNAL OF CANCER, 1990, 62 (01) :142-146
[6]   Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin:: a randomised crossover trial in advanced colorectal cancer [J].
Borner, MM ;
Schöffski, P ;
de Wit, R ;
Caponigro, F ;
Comella, G ;
Sulkes, A ;
Greim, G ;
Peters, GJ ;
van der Born, K ;
Wanders, J ;
de Boer, RF ;
Martin, C ;
Fumoleau, P .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) :349-358
[7]   FACTORS PREDICTING FOR RESPONSE, TIME TO TREATMENT FAILURE, AND SURVIVAL IN WOMEN WITH METASTATIC BREAST-CANCER TREATED WITH DAVTH - A PROSPECTIVE EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY [J].
FALKSON, G ;
GELMAN, R ;
FALKSON, CI ;
GLICK, J ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) :2153-2161
[8]  
FEY MF, 1981, CANCER CLIN TRIALS, V4, P237
[9]   Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer [J].
Fumoleau, P ;
Largillier, R ;
Clippe, C ;
Dièras, V ;
Orfeuvre, H ;
Lesimple, T ;
Culine, S ;
Audhuy, B ;
Serin, D ;
Curé, H ;
Vuillemin, E ;
Morère, JF ;
Montestruc, F ;
Mouri, Z ;
Namer, M .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (04) :536-542
[10]   PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].
GUSTERSON, BA ;
GELBER, RD ;
GOLDHIRSCH, A ;
PRICE, KN ;
SAVESODERBORGH, J ;
ANBAZHAGAN, R ;
STYLES, J ;
RUDENSTAM, CM ;
GOLOUH, R ;
REED, R ;
MARTINEZTELLO, F ;
TILTMAN, A ;
TORHORST, J ;
GRIGOLATO, P ;
BETTELHEIM, R ;
NEVILLE, AM ;
BURKI, K ;
CASTIGLIONE, M ;
COLLINS, J ;
LINDTNER, J ;
SENN, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056